Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.
Associated Press - Tuesday October 6, 1998
But hepatitis patients need to take lower doses of Epivir than patients who have the HIV virus that causes AIDS. If the FDA approves the drug's new use, Glaxo Wellcome Inc. would sell the appropriate dose under the brand name Epivir HBV. The FDA is not bound by advisory committee recommendations, but usually follows them.
But the advisory committee cautioned that no one yet knows how long hepatitis patients should take the drug, which was studied for just a year, or whether it helps patients with advanced hepatitis.
Epivir cannot cure hepatitis B, a virus that infects an estimated 1 million Americans. But it appears to target an enzyme important for the virus's reproduction, lowering the amount of hepatitis in patients' blood and improving the liver's health.
The only current FDA-approved treatment for hepatitis B is injected interferon. In one study of Americans with mild to moderate infection, 55 percent who took Epivir showed improvement when doctors took liver biopsies, vs. 25 percent of patients who took a dummy pill.
Doctors would have to test hepatitis patients for HIV before prescribing the drug, because patients with double infections would need the higher HIV dose, said FDA's Dr. Heidi Jolson. Also, no one is sure whether stopping Epivir could cause a dangerous hepatitis flare-up, she said.
981006
AP981005
Copyright © 1998 - Associated Press. Reproduction of this article (other than one copy for personal reference) must be cleared through the AP Permissions Desk.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, Pacific Life Foundation, and donations from users like you.
Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .